Cantor Fitzgerald Issues Positive Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price

Artiva Biotherapeutics (NASDAQ:ARTV) had its price objective increased by Cantor Fitzgerald from $10.00 to $40.00 in a report released on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts have also recently issued reports about the company. HC Wainwright boosted their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Wedbush boosted their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Needham & Company LLC reissued a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Monday, May 4th. Finally, Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

Artiva Biotherapeutics Trading Down 2.7%

Shares of NASDAQ ARTV opened at $10.60 on Monday. Artiva Biotherapeutics has a twelve month low of $1.47 and a twelve month high of $14.53. The stock has a fifty day simple moving average of $7.81 and a 200-day simple moving average of $5.43. The stock has a market capitalization of $262.03 million, a PE ratio of -2.99 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, equities analysts predict that Artiva Biotherapeutics will post -3.33 earnings per share for the current year.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ARTV. Citadel Advisors LLC lifted its holdings in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after purchasing an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets increased its position in Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after acquiring an additional 117,733 shares during the period. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics in the 4th quarter valued at about $341,000. Jane Street Group LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at about $67,000. Finally, Landscape Capital Management L.L.C. acquired a new position in Artiva Biotherapeutics in the 3rd quarter valued at about $112,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.